. 1	•*		
Please type a	plus sign (+) inside this box	→	+

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complet if Known Substitute for form 1449B/PTO 10/031037 **Application Number INFORMATION DISCLOSURE** May 13, 2002 **Filing Date** Stephen Douglas Barrett, et al. STATEMENT BY APPLICANT First Named Inventor 1614 Group Art Unit (use as many sheets as necessary) **Examiner Name** Sheet of **Attorney Docket Number** A0000102-01-SMH

	,	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner nitials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
621		ALESSI, Dario R., et al., "PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo", J. Biol. Chem., 1995, pp 27489-27494, Vol. 270, No. 46	
		HWANG, Daniel, et al., "Expression of Mitogen-Inducible Cyclooxygenase Induced by Lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-KB signaling pathways in macrophages", Biochem Pharm, 1997, pp 87-96, Vol. 54, Issue 1	
		LARRIVEE, Jean-François, et al., "Role of the Mitogen-Activated Protein Kinases in the Expression of the Kinin B1 Receptors Induced by Tissue Injury ", J Immunol, 1998, pp 1419-1426, Vol. 160, No. 3	
64 64		POLAKIEWICZ, Roberto D., et al., "A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization", J. Biol. Chem., 1998, pp 12402-12406. Vol. 273, No. 20	
		RECEIVED	1
		TECH CENTER 1600/2	23(
			+
Examine	. 17	Date 1/8/27	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

1

Sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB confrol Compl te if Kn wn 10/03 103 January 15, 2002

Stephen Douglas Barrett, et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Examiner Name Attorney Docket Number A0000102-01-SMH

Application Number

First Named Inventor

Filing Date

Group Art Unit

				U.S. PATENT DOCU	JMENTS	
Examiner Initials	Cite No.1	U.S. Patent Number	Cocument Kind Code ² (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
421		5,155,11		David T. Connor, et al.	10/13/1992	
					- 	
-			-		·	
	-				 	
		· · · · · · · · · · · · · · · · · · ·		· - .	 	
						· · · · · · · · · · · · · · · · · · ·
			\mathcal{A}	'a		
			- -			
	$\overline{}$				- 	
		·				

				FORI	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite		Foreign Patent Do	Kind Code ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
	No.Or	ic e ₂	Number ⁴	(if known)		MM-DD-YYYY	Figures Appear	Te
181		wo	98/37881	A1	Alexander J. Bridges	09/03/1998_		
54		wc	00/35436	A2	David T. Dudley, et al.	06/22/2000		
gri		WO	00/42022	A1	Stephen D. Barrett, et al	07/20/2000		
U.								
								$oldsymbol{ol}}}}}}}}}}}}}}}}}$

Examiner Signature Date Considered 1/8/05		
	1	1/8/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

USSN 10/031,037 Express Mail N

.EF220788517US PD-A0000102-01-SMH

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please typ	90 a	plus	sign (4) inside ti	nis box	→	\Box
, ,				,		•	l ' }

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449B/F			Complete if Known				
				Application Number	10/031037			
INFO	DRMATIC)N D	ISCLOSURE	Filing Date	January 15, 2002			
STATEMENT BY APPLICANT		First Named Inventor	Stephen Douglas Barrett, et al.					
• • • • • • • • • • • • • • • • • • • •				Group Art Unit				
	(use as man	y sheets	as necessary)	Examiner Name				
Sheet	2	of	2	Attorney Docket Number	A0000102-01-SMH			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cits No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
61		PCT International Search Report PCT/US00/18345	
		H. BEKEMEIER, et al., "Structure-Activity Relationship in Nonsteroidal Antinflammatory Agents, Including Qsar in Fenamate Derivatives", Agents and Actions Supplements, July 1, 1982, pp 17-34	
		J. V. DUNCIA, et al., "MEK Inhibitors: The Chemistry and Biological Activity of U0126, Its Analogs, and Cyclization Products", Bioorganic & Medicinal Chemistry Letters, 1998, pp 2839-2844, No. 8	brace
		N. S. DUESBERY, et al., "MEK Waars, a new front in the Battle Against Cancer", Nature Medicine, July 1999, pp 736-737, Vol. 5, No. 7	
5H		RU-RONG JI, et al., "Nociceptive-specific Activation of ERK in Spinal Neurons Contributes to Pain Hypersensitivity", Nature Neuroscience, December 1999, pp 1114-1119, Vol. 2, No. 12	
· <u></u>			
			+
Examine: Signature		Jan Att Date Considered 1/8/01	_

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.